Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by InnoCare Pharma

< Previous 1 2 Next >
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
From InnoCare Pharma
Via Business Wire
InnoCare Releases 2024 Results and Business Highlights
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China
From InnoCare Pharma
Via Business Wire
Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD
From InnoCare Pharma
Via Business Wire
Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum
From InnoCare Pharma
Via Business Wire
InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China
From InnoCare Pharma
Via Business Wire
InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China
From InnoCare Pharma
Via Business Wire
InnoCare Releases 2024 Interim Results and Business Highlights
From InnoCare Pharma
Via Business Wire
British Journal of Cancer: Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.
From InnoCare Pharma
Via Business Wire
InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China
From InnoCare Pharma
Via Business Wire
Data of InnoCare’s Robust Pipelines Presented at the European Hematology Association (EHA) 2024 Hybrid Congress
From InnoCare Pharma
Via Business Wire
InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA
From InnoCare Pharma
Via Business Wire
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
From InnoCare Pharma
Via Business Wire
InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
From InnoCare Pharma
Via Business Wire
InnoCare Releases 2023 Results and Business Highlights
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
From InnoCare Pharma
Via Business Wire
InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From InnoCare Pharma
Via Business Wire
InnoCare Appoints Xin Fu as Chief Financial Officer
From InnoCare Pharma
Via Business Wire
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis
From InnoCare Pharma
Via Business Wire
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH
From InnoCare Pharma
Via Business Wire
10 Studies on InnoCare’s Oncology Pipelines Selected at the Upcoming 65th Annual Meeting of ASH
From InnoCare Pharma
Via Business Wire
InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of Orelabrutinib for the Treatment of ITP in China
From InnoCare Pharma
Via Business Wire
InnoCare Announces Approval of Clinical Trial of SHP2 Inhibitor ICP-189 in Combination with EGFR Inhibitor Furmonertinib
From InnoCare Pharma
Via Business Wire
InnoCare Releases 2023 Interim Results and Business Highlights
From InnoCare Pharma
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.